These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 30069991

  • 1. Translocator protein 18kDa antagonist ameliorates stress-induced stool abnormality and abdominal pain in rodent stress models.
    Kawahara Y, Mitsui K, Niwa T, Morimoto N, Kawaharada S, Katsumata S.
    Neurogastroenterol Motil; 2018 Nov; 30(11):e13425. PubMed ID: 30069991
    [Abstract] [Full Text] [Related]

  • 2. Anti-stress effects of ONO-2952, a novel translocator protein 18 kDa antagonist, in rats.
    Mitsui K, Niwa T, Kawahara Y, Morimoto N, Ohmoto K, Kato M, Yamaura Y, Yoshimoto N, Suna H, Katsumata S.
    Neuropharmacology; 2015 Dec; 99():51-66. PubMed ID: 26189762
    [Abstract] [Full Text] [Related]

  • 3. Antidepressant effect of the translocator protein antagonist ONO-2952 on mouse behaviors under chronic social defeat stress.
    Nozaki K, Ito H, Ohgidani M, Yamawaki Y, Sahin EH, Kitajima T, Katsumata S, Yamawaki S, Kato TA, Aizawa H.
    Neuropharmacology; 2020 Jan 01; 162():107835. PubMed ID: 31682855
    [Abstract] [Full Text] [Related]

  • 4. Pharmacological evaluation of a novel corticotropin-releasing factor 1 receptor antagonist T-3047928 in stress-induced animal models in a comparison with alosetron.
    Itomi Y, Tanaka T, Matsushita K, Kawamura T, Kojima T, Aso K, Matsumoto-Okano S, Tsukimi Y.
    Neurogastroenterol Motil; 2020 May 01; 32(5):e13795. PubMed ID: 31970891
    [Abstract] [Full Text] [Related]

  • 5. Randomised clinical trial: exploratory phase 2 study of ONO-2952 in diarrhoea-predominant irritable bowel syndrome.
    Whitehead WE, Duffy K, Sharpe J, Nabata T, Bruce M.
    Aliment Pharmacol Ther; 2017 Jan 01; 45(1):14-26. PubMed ID: 27910150
    [Abstract] [Full Text] [Related]

  • 6. Quantification of ONO-2952 Occupancy of 18-kDaTranslocator Protein in Conscious Monkey Brains using Positron Emission Tomography.
    Mitsui K, Morimoto N, Niwa T, Yamaura Y, Ohba H, Tsukada H, Katsumata S.
    J Pharmacol Exp Ther; 2017 Mar 01; 360(3):457-465. PubMed ID: 27986860
    [Abstract] [Full Text] [Related]

  • 7. Effect of ramosetron on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats.
    Funatsu T, Takeuchi A, Hirata T, Keto Y, Akuzawa S, Sasamata M.
    Eur J Pharmacol; 2007 Nov 14; 573(1-3):190-5. PubMed ID: 17658508
    [Abstract] [Full Text] [Related]

  • 8. Abdominal pain in Irritable Bowel Syndrome: a review of putative psychological, neural and neuro-immune mechanisms.
    Elsenbruch S.
    Brain Behav Immun; 2011 Mar 14; 25(3):386-94. PubMed ID: 21094682
    [Abstract] [Full Text] [Related]

  • 9. Selective corticotropin-releasing factor 1 receptor antagonist E2508 reduces restraint stress-induced defecation and visceral pain in rat models.
    Taguchi R, Shikata K, Furuya Y, Hirakawa T, Ino M, Shin K, Shibata H.
    Psychoneuroendocrinology; 2017 Jan 14; 75():110-115. PubMed ID: 27810704
    [Abstract] [Full Text] [Related]

  • 10. Intestinal Fungal Dysbiosis Is Associated With Visceral Hypersensitivity in Patients With Irritable Bowel Syndrome and Rats.
    Botschuijver S, Roeselers G, Levin E, Jonkers DM, Welting O, Heinsbroek SEM, de Weerd HH, Boekhout T, Fornai M, Masclee AA, Schuren FHJ, de Jonge WJ, Seppen J, van den Wijngaard RM.
    Gastroenterology; 2017 Oct 14; 153(4):1026-1039. PubMed ID: 28624575
    [Abstract] [Full Text] [Related]

  • 11. Brain translocator protein occupancy by ONO-2952 in healthy adults: A Phase 1 PET study using [11 C]PBR28.
    Frankle WG, Narendran R, Wood AT, Suto F, Himes ML, Kobayashi M, Ohno T, Yamauchi A, Mitsui K, Duffy K, Bruce M.
    Synapse; 2017 Jul 14; 71(7):. PubMed ID: 28245513
    [Abstract] [Full Text] [Related]

  • 12. Visceral hypersensitivity in irritable bowel syndrome.
    Kanazawa M, Hongo M, Fukudo S.
    J Gastroenterol Hepatol; 2011 Apr 14; 26 Suppl 3():119-21. PubMed ID: 21443723
    [Abstract] [Full Text] [Related]

  • 13. Cumulative Effects of Psychologic Distress, Visceral Hypersensitivity, and Abnormal Transit on Patient-reported Outcomes in Irritable Bowel Syndrome.
    Simrén M, Törnblom H, Palsson OS, Van Oudenhove L, Whitehead WE, Tack J.
    Gastroenterology; 2019 Aug 14; 157(2):391-402.e2. PubMed ID: 31022401
    [Abstract] [Full Text] [Related]

  • 14. Lactulose Breath Test Gas Production in Childhood IBS Is Associated With Intestinal Transit and Bowel Movement Frequency.
    Chumpitazi BP, Weidler EM, Shulman RJ.
    J Pediatr Gastroenterol Nutr; 2017 Apr 14; 64(4):541-545. PubMed ID: 27276436
    [Abstract] [Full Text] [Related]

  • 15. Antinociceptive effect of chronic lithium on visceral hypersensitivity in a rat model of diarrhea-predominant irritable bowel syndrome: The role of nitric oxide pathway.
    Shamshiri H, Paragomi P, Paydar MJ, Moezi L, Bahadori M, Behfar B, Ardalan FA, Dehpour AR.
    J Gastroenterol Hepatol; 2009 Apr 14; 24(4):672-80. PubMed ID: 19032458
    [Abstract] [Full Text] [Related]

  • 16. [Efficacy of Kolofort for the treatment of patients with irritable bowel syndrome].
    Tsukanov VV, Rzhavicheva OS, Vasjutin AV, Dunaevskaja OV, Tonkih JL, Bronnikova EP.
    Ter Arkh; 2016 Apr 14; 88(8):40-45. PubMed ID: 27636926
    [Abstract] [Full Text] [Related]

  • 17. Pharmacological profile of ramosetron, a novel therapeutic agent for IBS.
    Hirata T, Funatsu T, Keto Y, Nakata M, Sasamata M.
    Inflammopharmacology; 2007 Feb 14; 15(1):5-9. PubMed ID: 17323187
    [Abstract] [Full Text] [Related]

  • 18. CRF1 receptors as a therapeutic target for irritable bowel syndrome.
    Martinez V, Taché Y.
    Curr Pharm Des; 2006 Feb 14; 12(31):4071-88. PubMed ID: 17100612
    [Abstract] [Full Text] [Related]

  • 19. 5-HT3 receptor antagonists. 3. Quinoline derivatives which may be effective in the therapy of irritable bowel syndrome.
    Kishibayashi N, Miwa Y, Hayashi H, Ishii A, Ichikawa S, Nonaka H, Yokoyama T, Suzuki F.
    J Med Chem; 1993 Oct 29; 36(22):3286-92. PubMed ID: 8230119
    [Abstract] [Full Text] [Related]

  • 20. Update on irritable bowel syndrome and gender differences.
    Heitkemper MM, Jarrett ME.
    Nutr Clin Pract; 2008 Oct 29; 23(3):275-83. PubMed ID: 18595860
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.